Home
Lymphoma Hub
Lymphoma Hub
VIRTUAL SYMPOSIUM

Customizing first-line BTK inhibitors for CLL

Wednesday, October 23, 2024
18:30–19:30 BST

Add to calendar

Agenda

18:30 (BST)
Gilles Salles

Welcome and introductions

  • Introduction to the Lymphoma Hub
  • Educational objectives and pre-symposium test
  • Introduction to the speakers
18:35 (BST)
Gilles Salles

Unmet needs with BTKis in CLL

  • Overview of the current treatment guidelines for BTKis
  • Real-world experience with BTKis
  • Live Q&A with the audience
18:50 (BST)
Paolo Ghia

BTKis: Current and future perspectives

  • Overview of emerging BTKis for CLL
  • Key efficacy and safety data from clinical trials
  • Live Q&A with the audience
19:05 (BST)
Francesc Bosch

BTKis in clinical practice for CLL: Case study clinic

  • Interactive case studies and panel discussion to review optimal treatment selection for CLL in patient subgroups, including high- versus low-risk patients, sequencing strategies, dosing flexibility, and the role of minimal residual disease
  • Live Q&A with the audience
19:25 (BST)
Gilles Salles

Closing remarks and evaluation

  • Post-symposium test and event evaluation

Learning objectives

Upon completion of this activity, participants should be able to:

  • Describe novel therapeutic targets in CLL and explain the mechanisms of action for new agents.
  • Recall the latest data for new agents, including their regulatory status in CLL, and describe the rationale for selecting such treatments based on previous treatments and patient-related factors.
  • Describe the adverse event profiles of novel agents, and state how adverse events could be managed in clinical practice.

Our speakers

Meet our panel of experts

Gilles Salles

Memorial Sloan Kettering Cancer Center

New York, US

Paolo Ghia

Università Vita-Salute San Raffaele

Milan, IT

Francesc Bosch

Vall d'Hebron Barcelona Hospital Campus

Barcelona, ES
Scientific Education Support (SES)

About SES

Delivering streamlined independent medical education to enhance clinical practice. SES hubs allow time-stretched healthcare professionals to easily access curated scientific, medical, and clinical information that expedites their learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, our hubs support healthcare professionals worldwide with up-to-date, accessible, and impactful educational content.

Lymphoma Hub

About the Lymphoma Hub

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

The Lymphoma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

Registration form

Registration is free. Please complete the form and submit to register.


The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy